Brokerages expect that PetMed Express, Inc. (NASDAQ:PETS) will announce sales of $57.02 million for the current quarter, Zacks reports. Three analysts have issued estimates for PetMed Express’ earnings, with estimates ranging from $55.66 million to $58.50 million. PetMed Express posted sales of $52.87 million during the same quarter last year, which would indicate a positive year over year growth rate of 7.8%. The company is scheduled to report its next earnings report on Monday, January 22nd.
On average, analysts expect that PetMed Express will report full year sales of $57.02 million for the current financial year, with estimates ranging from $270.90 million to $271.87 million. For the next fiscal year, analysts expect that the business will report sales of $291.80 million per share, with estimates ranging from $291.60 million to $292.00 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow PetMed Express.
PetMed Express (NASDAQ:PETS) last released its earnings results on Monday, October 23rd. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.30 by $0.13. PetMed Express had a net margin of 11.58% and a return on equity of 31.46%. The company had revenue of $66.70 million during the quarter, compared to the consensus estimate of $63.41 million. During the same quarter in the prior year, the firm earned $0.24 EPS. The company’s revenue was up 9.7% compared to the same quarter last year.
PETS has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of PetMed Express from a “sell” rating to a “hold” rating and set a $50.00 target price for the company in a research report on Friday, October 20th. BidaskClub upgraded shares of PetMed Express from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 9th. Noble Financial reiterated a “hold” rating on shares of PetMed Express in a research report on Friday, October 27th. Northcoast Research set a $58.00 target price on shares of PetMed Express and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. Finally, ValuEngine downgraded shares of PetMed Express from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $42.80.
In other news, Director Ronald J. Korn sold 1,000 shares of the stock in a transaction on Friday, October 27th. The shares were sold at an average price of $35.57, for a total transaction of $35,570.00. Following the transaction, the director now owns 73,833 shares in the company, valued at approximately $2,626,239.81. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gian Fulgoni sold 20,000 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $44.38, for a total transaction of $887,600.00. Following the transaction, the director now owns 55,900 shares in the company, valued at approximately $2,480,842. The disclosure for this sale can be found here. Corporate insiders own 4.00% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its stake in shares of PetMed Express by 120.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 157,963 shares of the company’s stock worth $6,413,000 after purchasing an additional 86,375 shares during the last quarter. Royal Bank of Canada increased its stake in shares of PetMed Express by 86.5% during the 2nd quarter. Royal Bank of Canada now owns 8,337 shares of the company’s stock worth $338,000 after purchasing an additional 3,867 shares during the last quarter. Prudential Financial Inc. increased its stake in shares of PetMed Express by 552.8% during the 3rd quarter. Prudential Financial Inc. now owns 824,434 shares of the company’s stock worth $27,330,000 after purchasing an additional 698,140 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of PetMed Express by 8.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 860,601 shares of the company’s stock worth $34,940,000 after purchasing an additional 65,932 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. acquired a new position in shares of PetMed Express during the 3rd quarter worth $2,558,000. Institutional investors own 99.88% of the company’s stock.
Shares of PetMed Express (NASDAQ:PETS) opened at $52.95 on Friday. PetMed Express has a 12-month low of $19.21 and a 12-month high of $53.32. The stock has a market cap of $1,090.78, a P/E ratio of 35.53, a price-to-earnings-growth ratio of 3.15 and a beta of 1.12.
TRADEMARK VIOLATION WARNING: “PetMed Express, Inc. (PETS) Expected to Post Quarterly Sales of $57.02 Million” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/14/petmed-express-inc-pets-expected-to-post-quarterly-sales-of-57-02-million.html.
PetMed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Get a free copy of the Zacks research report on PetMed Express (PETS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.